Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Down 9% in 2020, Is Biogen Now a Buy?

By Jason Hawthorne - Dec 17, 2020 at 6:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company isn't standing still while its Alzheimer's drug is up in the air.

Biogen ( BIIB 1.38% ) had a wild 2020. In November, reviewers from the Food and Drug Administration (FDA) seemed to endorse the company's potential Alzheimer's drug aducanumab, sending the shares up 44%. A few days later, an advisory panel overwhelmingly said there was not strong evidence that the drug was effective, sending shares back down.

An official decision will come by March. While investors wait, a lot is happening at the $36 billion biotech company.

A lady in a hospital gown looking at brain scans that her doctor is holding.

Image source: Getty Images

Competition heats up

Biogen is primarily focused on neurological disorders, with most of its $14.3 billion annual revenue coming from multiple sclerosis (MS) drugs. For the first nine months of 2020, the MS drugs have declined less than 1%. But things are starting to get worse. 

After two court rulings this summer, generics are hitting the market and eroding the $3.3 billion in annual sales of the company's flagship drug Tecfidera. The competition caused Biogen management to cut full-year 2020 sales and earnings forecasts in October, but they've been making deals to fill the hole.

The promise of partnerships

The deals are all with smaller biotechs to jointly develop drugs. In August, it was Denali Therapeutics and a treatment for Parkinson's disease. In October, it was a research pact with Scribe Therapeutics to develop CRISPR-based medicines. Finally, in November, the company announced a $1.5 billion investment in Sage Therapeutics to jointly develop depression drug zuranolone

All of these deals also come with additional rights for Biogen that have breakthrough potential, but the market isn't giving management a lot of credit. The stock is trading at its lowest price-to-sales ratio in a decade.

While it seems there's enough potential to justify buying shares, the same could be said for Gilead Sciences when its sales peaked in 2015. I think Biogen stock is in the hold bucket for now. There'll be plenty of time to buy shares if any of the partnerships or internal programs start showing promise.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
$227.20 (1.38%) $3.09
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$69.55 (0.07%) $0.05
Sage Therapeutics, Inc. Stock Quote
Sage Therapeutics, Inc.
$39.74 (6.00%) $2.25
Denali Therapeutics Inc. Stock Quote
Denali Therapeutics Inc.
$44.30 (2.94%) $1.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.